Mr. Tony O'Brien:

I can only speak at this stage in terms of the reaction we have received. It is too early to see the hard data, for example, on last week's launch on the PPIs and the statins. The reaction back to our offices from those who have received the preferred medication guidance has been very positive and in fact numbers of people have encouraged us to consistently do this, do more of it and to be constantly coming out with messages. So the prescriber community seems to be responding very positively for it.